Physician profile

Michael B Wert

Pulmonary Disease · Greensboro, NC

NPI 1558310276

$412,133.05

in general payments reported to CMS, 2019-2025

44 companies · $53K in 2025

The $53K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$120,117.50
Food and Beverage$9,439.50
Travel and Lodging$6,211.56
Education$61.53

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $319,001.08 2019-2025 Breztri, Airsupra, Fasenra
Mylan Specialty L.P. $65,563.42 2019-2024 Yupelri, Yupelri
Glaxosmithkline, LLC. $17,428.18 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Viatris Specialty LLC $2,009.42 2025 Yupelri
Boehringer Ingelheim Pharmaceuticals, INC. $1,279.43 2019-2025 Ofev, Jardiance, Jascayd
United Therapeutics Corporation $723.83 2020-2025 Tyvaso, Tyvaso, Orenitram
Insmed, INC. $602.75 2019-2025 Arikayce, Brinsupri
Takeda Pharmaceuticals U.S.A., INC. $535.97 2020-2025 Glassia
Regeneron Healthcare Solutions, INC. $483.53 2019-2025 Dupixent
Novartis Pharmaceuticals Corporation $450.72 2019-2024
Grifols USA, LLC $325.04 2019-2024 Prolastin-C Liquid
Genzyme Corporation $321.98 2019-2025
Merck Sharp & Dohme LLC $314.75 2019-2025 Dificid, Zerbaxa, Winrevair
Actelion Pharmaceuticals US, INC. $309.16 2019-2025 Uptravi, Opsumit
Verona Pharma, INC. $238.26 2025 Ohtuvayre
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Sunovion Pharmaceuticals INC. $236.29 2019-2020
Electromed, INC. $228.48 2019-2024 Smartvest
Philips North America LLC $212.38 2019-2023
Genentech USA, INC. $191.10 2019
Abbvie INC. $148.71 2021-2024 Teflaro, Avycaz
Amgen INC. $140.91 2021-2024 Tezspire
Circassia INC. $139.37 2019-2020
Baxter Healthcare $130.42 2022-2024 Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System
Inogen, INC. $116.45 2022-2024 Inogen
Teva Pharmaceuticals USA, INC. $110.03 2021-2023
Harmony Biosciences LLC $108.95 2022-2024
Janssen Pharmaceuticals, INC $103.87 2020-2021
Alexion Pharmaceuticals, INC. $89.97 2019-2020
Shionogi INC $87.67 2022-2024 Fetroja
La Jolla Pharmaceutical Company $77.73 2019-2022
Breas Medical, INC. $61.47 2024 Vivo 45 Ls
Mallinckrodt Hospital Products INC. $58.49 2020-2023 Acthar
Allergan, INC. $56.27 2019-2020
Phathom Pharmaceuticals, INC. $39.83 2025 Voquezna
Tersera Therapeutics LLC $33.48 2022
Exact Sciences Corporation $30.55 2023 Cologuard Collection Kit
Gilead Sciences, INC. $24.63 2019-2022
Alcresta Therapeutics, INC. $22.94 2025 Relizorb
Bard Peripheral Vascular, INC. $20.95 2020
Novo Nordisk INC $19.26 2024
Avadel Cns Pharmaceuticals, LLC $18.32 2024 Lumryz
Pulmonx Corporation $13.38 2023 Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter
Bayer Healthcare Pharmaceuticals INC. $11.95 2022
Quidel Corporation $11.68 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael B Wert

$412,133.05

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $53K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/252181/michael-b-wert

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.